Prof Diana Lüftner speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the assessment of monoclonal antibodies from a physician's perspective.
She outlines the features that these clinical trials must include for approval - including pharmacodynamics, pharmacokinetics and response rates.
Prof Lüftner describes a particular clinical trial which aims to assess the switching process between agents.
She also explains how a physician should decide whether to use a biosimilar or the originator product.
Prof Lüftner also believes that biosimilars will become the standard of care for the future.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.